Press Release
G2GBio has the best subject matter experts in the field of the injectable drug development.
|
G2GBIO reveals data showing three-month sustained efficacy of its obesity and CNS treatment agent
2025.11.05
HIT 6762
|
|---|
|
G2GBIO, a company specializing in the development of sustained-release formulations, announced its participation in the ‘Partnership Opportunities in Drug Delivery (PODD)’ conference, held in Boston, USA, on October 27 and 28 (local time). During the event, the company delivered a presentation on the topic, ‘Innovative Ultra-High Drug-Loaded Microsphere Injectables for CNS and Metabolic Diseases.’ G2GBIO presented key pipeline research findings on high-dose formulations developed using its proprietary ‘InnoLAMP’ drug delivery platform. Specifically, the data included results from ‘GB-5001A (development code),’ a dementia treatment candidate that has completed Phase 1 clinical trials in Korea and Canada, as well as ‘GB-5021’ and ‘GB-5023,’ candidates for the treatment of schizophrenia. Notably, GB-5001A demonstrated pharmacokinetic (PK) activity lasting over 98 days in clinical studies, and the potential for a two- to -three-month sustained-release formulation was also highlighted during the PODD presentation. G2GBIO additionally presented pharmacokinetic (PK) data for a three-month formulation based on semaglutide, a drug used in the treatment of diabetes and obesity. The company has completed development of a one-month semaglutide formulation and plans to initiate clinical trials in the first half of next year. It is further noted that the three-month formulation is currently in the optimization phase and is approaching completion. G2GBIO is developing a long-acting injection formulation designed to maintain efficacy for over three months, utilizing its proprietary the InnoLAMP technology. The InnoLAMP platform enables more than a twofold increase in bioavailability by incorporating microspheres loaded with small-molecule compounds at concentrations exceeding 60%. “At this year’s PODD, we engaged in discussions on future directions with three global pharmaceutical companies with whom we had previously signed co-development agreements, and we also explored potential partnerships with new global major pharmaceutical firms,” a G2GBIO official said. “Our global collaborations are expanding as we continue to share robust data based on positive non-clinical and clinical results in the CNS field, where patient medication adherence remains a significant challenge.” |